Taysha Gene Therapies ROE 2020-2026 | TSHA
Current and historical return on equity (ROE) values for Taysha Gene Therapies (TSHA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Taysha Gene Therapies ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-03-31 | $-0.13B | $0.23B | -56.09% |
| 2025-12-31 | $-0.11B | $0.19B | -57.14% |
| 2025-09-30 | $-0.10B | $0.15B | -67.90% |
| 2025-06-30 | $-0.09B | $0.12B | -80.86% |
| 2025-03-31 | $-0.09B | $0.08B | -108.31% |
| 2024-12-31 | $-0.09B | $0.08B | -111.11% |
| 2024-09-30 | $-0.02B | $0.08B | -28.13% |
| 2024-06-30 | $-0.11B | $0.05B | -241.27% |
| 2024-03-31 | $-0.12B | $0.01B | -1097.67% |
| 2023-12-31 | $-0.11B | $-0.01B | 1723.08% |
| 2023-09-30 | $-0.22B | $-0.03B | 860.00% |
| 2023-06-30 | $-0.13B | $-0.01B | 1250.00% |
| 2023-03-31 | $-0.13B | $0.01B | -1786.67% |
| 2022-12-31 | $-0.17B | $0.02B | -691.67% |
| 2022-09-30 | $-0.16B | $0.05B | -338.95% |
| 2022-06-30 | $-0.19B | $0.08B | -231.97% |
| 2022-03-31 | $-0.19B | $0.12B | -162.71% |
| 2021-12-31 | $-0.17B | $0.16B | -108.07% |
| 2021-09-30 | $-0.14B | $0.20B | -71.00% |
| 2021-06-30 | $-0.11B | $0.23B | -45.69% |
| 2021-03-31 | $-0.09B | $0.19B | -46.36% |
| 2020-12-31 | $-0.06B | $0.13B | -45.47% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |